![]() |
![]() |
|
多克隆抗T细胞球蛋白是儿科异源干细胞移植的准备治疗方法
Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. To prevent graft rejection and graft-versus-host
disease (GvHD) after allogeneic stem-cell transplantation (ASCT), 56 children
were given polyclonal anti-T-cell globulin (ATG) as part of the conditioning
regimen. Of the 56 children in the cohort, 27 had a non-malignant disease
and 29 had different hematological malignancies. Eight were in first remission
of leukemia and the remainder in later stages. Donors were in 16 cases
a human leucocyte antigen (HLA)-identical sibling and in 40 a matched
unrelated donor (MUD). The control group comprised 16 patients with an
HLA-identical donor; the children in this group were not treated with
ATG. Side-effects related to the ATG treatment occured in 63% of the patients
and included fever, chills, headache, dyspnoea, nausea/vomiting, body
pain, fall in blood pressure, and transient respiratory arrest. Engraftment
occured in 55 (98%) of the ATG-treated patients at a median of 17 (11-27)
days after ASCT. One rejection occured at 23 days post-SCT. The probabilities
of acute graft-versus-host disease (GvHD) of grades II-IV were 6% for
patients with an HLA-identical donor, 12% for controls, and 26% for the
MUD group. Chronic GvHD occured in 20%, 50%, and 50% of patients in the
three groups, respectively. Transplant-related mortality rates at 100
days were 6%, 6%, and 7%, respectively. The 5-yr survival rate was 94%
and 81% using sibling donors, with and without ATG respectively, and 53%
using unrelated donors (p = 0.002). Disregarding donor type, among the
ATG-treated patients 5-yr survival rates were 46% in patients with a malignant
disease and 77% in non-malignant disorders. Relapse and relapse-free survival
rates were 42% and 46%, respectively. Five out of 12 patients who showed
an early full donor chimerism in the T-cell lineage developed acute GvHD
of grades II-IV, compared to none out of 13 patients being mixed chimeras
(p = 0.01). Hence, the use of polyclonal ATG as part of conditioning prior
to ASCT in children is safe and the survival rate encouraging. |